Category: NASDAQ News

Ziopharm Oncology (ZIOP) Receives FDA Fast Track Designation for Ad-RTS-hIL-12 plus Veledimex for Treatment of Recurrent Glioblastoma

Ziopharm Oncology, Inc. (Nasdaq: ZIOP), a clinical stage immuno-oncology company developing next generation cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its Controlled IL-12 program, or Ad-RTS-hIL-12 plus veledimex, for the treatment of recurrent or progressive glioblastoma multiforme (rGBM) in adults. “Recurrent glioblastoma multiforme […]

Continue Reading

Village Farms International’s (TSX: VFF) (NASDAQ: VFF) Pure Sunfarms Doubles Targeted Annual Production to 150,000 Kilograms by Exercising its Option on Village Farms-Owned 1.1 Million Square Foot Delta 2 Greenhouse Facility

VANCOUVER, April 1, 2019 /PRNewswire/ – Village Farms International, Inc. (“Village Farms” or the “Company”)  (TSX: VFF) (NASDAQ: VFF) today announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has exercised its option on the existing 1.1 million square foot Delta 2 greenhouse facility currently owned by Village Farms in Delta, British Columbia.  The […]

Continue Reading

Phio and Glycostem (NASDAQ:PHIO) to Collaborate on Use of its sd-rxRNA® platform and Glycostem’s oNKord® Cell Therapy Products for the Next Generation of Natural Killer Cell-based Immunotherapy for Cancer Treatment

MARLBOROUGH, Mass., March 28, 2019 /PRNewswire/ — Phio Pharmaceuticals Corp. (NASDAQ:PHIO) announced today that it has entered into a research collaboration with Glycostem Therapeutics BV to explore the potential synergies of using Phio’s self-delivering RNAi technology (sd-rxRNA®) in combination with Glycostem’s proprietary Natural Killer-cell (NK-cell) generation technology (oNKord®) to develop cellular immunotherapies for cancer treatment with […]

Continue Reading

How The African Cannabis Market Could Reach $7.1B By 2023

In the global cannabis landscape, Africa is an overlooked market. This is due to a number of factors, such as the illegality of the plant across the continent and the poor economic conditions that many African countries face. Africa has the potential to become an enormous cannabis market due to the large population and favorable climate that […]

Continue Reading

Cronos Group Inc. Announces Fourth Quarter 2018 and Full Year 2018 Results

Closed C$2.4 Billion Strategic Growth Investment from Altria Group, Inc. Completed first harvest in Peace Naturals expansion to Building 4 Launched Two Recreational Brands: COVE(TM) and Spinach(TM) Announced Landmark Partnership with Ginkgo Bioworks to Produce Cultured Cannabinoids Became first Pure Play Cannabis Company to list on a Major U.S. Exchange Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON.TO) […]

Continue Reading

Aldeyra Therapeutics (NASDAQ: ALDX) Announces Positive Top-Line Results from the Phase 3 ALLEVIATE Trial in Patients with Allergic Conjunctivitis

Primary endpoint of ocular itch score area under the curve achieved for both tested reproxalap concentrations – Key secondary endpoint of clinically relevant two-point ocular itch score improvement achieved for both tested reproxalap concentrations – Company closed on $60 million term loan facility LEXINGTON, Mass., March 26, 2019 /PRNewswire/ — Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a […]

Continue Reading

Immutep (NASDAQ: IMMP) Announces United States Patent Grant for Eftilagimod Alpha in Cancer

SYDNEY, Australia, March 21, 2019 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ:IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new patent (number 10,232,038) entitled “Use of Recombinant LAG-3 or the Derivatives thereof for Eliciting Monocyte Immune Response” by the […]

Continue Reading

Altimmune (NASDAQ: ALT) Announces Positive Results from NasoVAX Extension Study

Seroprotective HAI antibody response persisted more than one year after vaccination Company seeking partnership for further development and commercialization of NasoVAX GAITHERSBURG, Md., March 19, 2019 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced additional positive data from a Phase 2 extension study of its NasoVAX intranasal influenza vaccine candidate. Data […]

Continue Reading

Shineco, Inc. ( NASDAQ: TYHT) Establishes Subsidiary to Capture Industrial Cannabis Market Growth BEIJING, March. 18,

BEIJING, March. 18, 2019 /PRNewswire/ — Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: TYHT), a producer and distributor of Chinese herbal medicines, organic agricultural produce, specialized textiles, and other health and well-being focused plant-based products in China, announced today that the Company has established a wholly owned subsidiary, Beijing Tenjove Newhemp Biotechnology Co., Ltd. (“TNB”) on March […]

Continue Reading

Positive FDA Meeting Outlines Path Ahead for Akari Therapeutics’s ( Nasdaq: AKTX) Coversin in Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)

HSCT-TMA trial in pediatric patients expected to start Q4 2019 following recent FDA feedback NEW YORK and LONDON, March 13, 2019 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announces that it had […]

Continue Reading

Facebook